Tokyo Tape
Sign in
← OncoTherapy Science

Quarterly report · Q3

4564.TEDINET S100Q6XE
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 32
MetricValuePeriodScopeSource row
Revenue¥700m2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥335m2021-04-01 → 2021-12-31Cons.Net sales
Operating income−¥905m2022-04-01 → 2022-12-31Cons.Operating income
Operating income−¥1.7bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income−¥929m2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income−¥2.1bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.7bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax−¥912m2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax−¥2.1bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)−¥913m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.1bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income−¥913m2022-04-01 → 2022-12-31Cons.Profit loss
Net income−¥2.1bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥1.4bnat 2022-12-31Cons.Assets
Total assets¥2.7bnat 2022-03-31Cons.Assets
Total assets¥2.9bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥392mat 2022-12-31Cons.Liabilities
Total liabilities¥705mat 2022-03-31Cons.Liabilities
Net assets / equity¥1.1bnat 2022-12-31Cons.Net assets
Net assets / equity¥2.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥2.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥978mat 2022-12-31Cons.Cash and deposits
Cash and deposits¥1.8bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥-4.742022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.552022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-13.722021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-11.522021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-4.732021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio68.1%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio70.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio80.5%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 29
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥172,000
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥172,000
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥290m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥691m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥691m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2022-04-01 → 2022-12-31−¥79m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2022-04-01 → 2022-12-31¥9m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2022-04-01 → 2022-12-31¥9m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥172,000
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2022-04-01 → 2022-12-31−¥536m
—segment totalrevenue2022-04-01 → 2022-12-31¥700m
—segment totalrevenue external2022-04-01 → 2022-12-31¥700m
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥172,000
—segment totalsegment profit2022-04-01 → 2022-12-31−¥615m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥8m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥8m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥282m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥337m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥329m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥8m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2021-04-01 → 2021-12-31−¥127m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2021-04-01 → 2021-12-31¥7m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2021-04-01 → 2021-12-31¥7m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥132,000
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2021-04-01 → 2021-12-31−¥1.3bn
—segment totalrevenue2021-04-01 → 2021-12-31¥344m
—segment totalrevenue external2021-04-01 → 2021-12-31¥335m
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥8m
—segment totalsegment profit2021-04-01 → 2021-12-31−¥1.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 322
ItemContextValueUnit
Other noiPrior1YTDDuration0JPY
Other noiCurrentYTDDuration－JPY
Non operating incomePrior1YTDDuration819000JPY
Non operating incomeCurrentYTDDuration218000JPY
Stock issuance cost noePrior1YTDDuration4893000JPY
Stock issuance cost noeCurrentYTDDuration－JPY
Foreign exchange losses noePrior1YTDDuration7321000JPY
Foreign exchange losses noeCurrentYTDDuration8015000JPY
Relocation expenses noePrior1YTDDuration－JPY
Relocation expenses noeCurrentYTDDuration16161000JPY
Non operating expensesPrior1YTDDuration12215000JPY
Non operating expensesCurrentYTDDuration24176000JPY
Ordinary incomePrior1YTDDuration-1721711000JPY
Ordinary incomeCurrentYTDDuration-928906000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration49000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration－JPY
Gain on reversal of subscription rights to shares eiPrior1YTDDuration49201000JPY
Gain on reversal of subscription rights to shares eiCurrentYTDDuration37755000JPY
Extraordinary incomePrior1YTDDuration49250000JPY
Extraordinary incomeCurrentYTDDuration37755000JPY
Impairment loss elPrior1YTDDuration465428000JPY
Impairment loss elCurrentYTDDuration20398000JPY
Extraordinary lossPrior1YTDDuration465428000JPY
Extraordinary lossCurrentYTDDuration20398000JPY
Income before income taxesPrior1YTDDuration-2137889000JPY
Income before income taxesCurrentYTDDuration-911549000JPY
Income taxes currentPrior1YTDDuration2172000JPY
Income taxes currentCurrentYTDDuration1986000JPY
Income taxes deferredPrior1YTDDuration-850000JPY
Income taxes deferredCurrentYTDDuration-338000JPY
Income taxesPrior1YTDDuration1321000JPY
Income taxesCurrentYTDDuration1648000JPY
Profit lossPrior1YTDDuration-2139211000JPY
Profit lossCurrentYTDDuration-913197000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-2139211000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-913197000JPY
Profit lossPrior1YTDDuration-2139211000JPY
Profit lossCurrentYTDDuration-913197000JPY
Comprehensive incomePrior1YTDDuration-2139211000JPY
Comprehensive incomeCurrentYTDDuration-913197000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration-2139211000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration-913197000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember6577000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember328636000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember335214000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration335214000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember132000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember8333000JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember8465000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass